Literature DB >> 18838746

Renal dysfunction and tenofovir toxicity in HIV-infected patients.

Lynda A Szczech1.   

Abstract

Potentially nephrotoxic drugs are only 1 of several causes of renal dysfunction in HIV. Data from the period before the wide use of tenofovir show a variety of prerenal, renal, and obstructive causes of acute renal failure (ARF) in HIV outpatients. Results of clinical trials of tenofovir indicate a rate of ARF of approximately 1%, with observational cohort data indicating a somewhat higher rate. Thus, in evaluating patients with rising serum creatinine levels, including those receiving tenofovir, diagnostic efforts should go beyond discontinuation of potentially offending drugs. This article summarizes a presentation on renal dysfunction in HIV and renal toxicity of antiretroviral drugs made by Lynda A. Szczech, MD, MSCE, at an International AIDS Society-USA Continuing Medical Education course in Washington, DC, in May 2008. The original presentation is available as a Webcast at www.iasusa.org.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838746

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  20 in total

Review 1.  Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.

Authors:  Douglas Krakower; Kenneth H Mayer
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

Review 2.  Antiretroviral treatment interruptions and risk of non-opportunistic diseases.

Authors:  Kenneth A Lichtenstein
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

3.  Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice.

Authors:  Hanna H Ng; Howard Stock; Linda Rausch; Deborah Bunin; Abraham Wang; Shirley Brill; Jason Gow; Jon C Mirsalis
Journal:  Int J Toxicol       Date:  2015-01-07       Impact factor: 2.032

Review 4.  HIV therapies and the kidney: some good, some not so good?

Authors:  Lene Ryom; Amanda Mocroft; Jens Lundgren
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

5.  Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

Authors:  Jennifer R King; Ram Yogev; Patrick Jean-Philippe; Bobbie Graham; Andrew Wiznia; Paula Britto; Vincent Carey; Rohan Hazra; Edward P Acosta
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

6.  Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

Authors:  E Randall Lanier; Roger G Ptak; Bernhard M Lampert; Laurie Keilholz; Tracy Hartman; Robert W Buckheit; Marie K Mankowski; Mark C Osterling; Merrick R Almond; George R Painter
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 7.  What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.

Authors:  Douglas Krakower; Kenneth H Mayer
Journal:  Ann Intern Med       Date:  2012-10-02       Impact factor: 25.391

8.  Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.

Authors:  S M Baxi; R M Greenblatt; P Bacchetti; M Cohen; J A DeHovitz; K Anastos; S J Gange; M A Young; B E Aouizerat
Journal:  Pharmacogenomics J       Date:  2017-05-02       Impact factor: 3.550

9.  Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.

Authors:  Francine Touzard Romo; Mariam Aziz; Britt Livak; Emily Huesgen; Ben Colton; Timothy P Flanigan; Blake Max; Harold Kessler
Journal:  J AIDS Clin Res       Date:  2014-11

Review 10.  Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.

Authors:  Emma D Deeks; Caroline M Perry
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.